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Background: Clinicians face challenges in promoting colorectal cancer screening due to multiple competing
demands. A decision aid that clarifies patient preferences and improves decision quality can aid shared decision
making and be effective at increasing colorectal cancer screening rates. However, exactly how such an intervention
improves shared decision making is unclear. This study, funded by the National Cancer Institute, seeks to provide
detailed understanding of how an interactive decision aid that elicits patient’s risks and preferences impacts
patient-clinician communication and shared decision making, and ultimately colorectal cancer screening adherence.
Methods/Design: This is a two-armed single-blinded randomized controlled trial with the target of 300 patients
per arm. The setting is eleven community and three academic primary care practices in Metro Detroit. Patients are
men and women aged between 50 and 75 years who are not up to date on colorectal cancer screening.
ColoDATES Web (intervention arm), a decision aid that incorporates interactive personal risk assessment and
preference clarification tools, is compared to a non-interactive website that matches ColoDATES Web in content
but does not contain interactive tools (control arm). Primary outcomes are patient uptake of colorectal cancer
screening; patient decision quality (knowledge, preference clarification, intent); clinician’s degree of shared decision
making; and patient-clinician concordance in the screening test chosen. Secondary outcome incorporates a
Structural Equation Modeling approach to understand the mechanism of the causal pathway and test the validity
of the proposed conceptual model based on Theory of Planned Behavior. Clinicians and those performing the
analysis are blinded to arms.
Discussion: The central hypothesis is that ColoDATES Web will improve colorectal cancer screening adherence
through improvement in patient behavioral factors, shared decision making between the patient and the clinician,
and concordance between the patient’s and clinician’s preferred colorectal cancer screening test. The results of this
study will be among the first to examine the effect of a real-time preference assessment exercise on colorectal
cancer screening and mediators, and, in doing so, will shed light on the patient-clinician communication and
shared decision making ‘black box’ that currently exists between the delivery of decision aids to patients and
subsequent patient behavior.
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Colorectal cancer screening (CRCS) is recommended for
all average-risk United States (US) adults aged ≥ 50 years,
because it reduces colorectal cancer (CRC) death and
morbidity [1-6]. Unlike other countries, cancer screening
in the US is almost always done within the context of
patients’ office visits to their clinicians. In the US, sev-
eral CRCS options are available including stool blood
test, flexible sigmoidoscopy, and colonoscopy, unless the
adult is at increased risk for CRC in which case the test
option is limited to colonoscopy [1,3,7]. CRCS rates have
shown an upward trend, with overall screening rates in-
creasing from 20% in 1997 to nearly 65% in 2010 [8].
However, millions of eligible people remain unscreened
by any method [9,10]. No strong evidence exists that fa-
vors one CRCS test over another for reducing CRC mor-
tality [1,2]. The US Preventive Services Task Force, the
American Cancer Society, and the National Institutes of
Health State-of-the-Science Conference recommend
that, in order to optimize the CRCS rate, CRCS should
be based on patient preferences [1,2,9,11,12].
Patient preferences for CRCS are highly variable and
relate to particular test characteristics of efficacy, sen-
sitivity, cost, complexity, and possible harm [13-23]. Pa-
tient preference clarification does not mean merely
offering choices without guidance: when the information
and options are not provided within the context of their
preferences and values, patients’ ability to make a deci-
sion may actually decrease [24-28]. Clinicians are en-
couraged to incorporate patient values when discussing
CRCS and eliciting their screening choice, counselling
patients to choose the CRCS test most congruous with
their preferences and values [11,23,29]. Shared decision
making (SDM) recognizes the central role of the patient-
clinician relationship in helping patients make such
decisions [29,30]. However, SDM requires more time
and resources than most clinicians have for a single
issue, especially with multiple, competing agendas
[31-34]. Also, clinicians do not always correctly perceive
and address those factors important to patients and may
not have the training and skills to provide effective SDM
[23,30,33,35-38].
Decision aids (DAs) can potentially facilitate SDM by
reducing patient decisional conflict, improving patient
knowledge, and stimulating patients to be more active in
decision making without increasing anxiety [39]. They
usually include information on the disease/condition
and the associated tests/treatments, probabilities of out-
comes (benefits and harms) for each test/treatment op-
tion, and some form of a values clarification exercise to
help patients determine which option would best match
their values. Studies utilizing DAs by video, informed
consent, and analytical hierarchy process have shown
small increases in CRCS [40-42]. However, an importantstep that has not been evaluated to date is how the pa-
tients activated by DAs subsequently communicate with
their clinicians, and whether the patients and clinicians
are able to engage in SDM at a level consistent with the
patients’ desires. This is important, because the clini-
cian’s recommendation has a significant impact on
patients’ behavior change, including CRCS adherence
[43-45].
We have developed ColoDATES Web (CW), an inter-
active decision aid (DA) for CRCS designed to be used
prior to a clinic visit to clarify patients’ preferences, pro-
mote SDM, and increase CRCS adherence [46-48]. It
was developed through extensive formative research.
First, focus groups of unscreened adults aged 50 to
64 years in three communities (urban, suburban, and
rural) in Michigan, USA, revealed a clear enthusiasm for
something to help individuals decide among the CRCS
options, and the Internet as the ideal information source
[46]. Next, an Internet search of over 65 English lan-
guage websites on CRCS targeting American adults re-
vealed little factual variation, user-directed navigation
without guidance, high reading level text format, lack of
readily available risk assessment tool, and lack of inter-
active assistance to establish CRCS preference [47].
These findings led to the development of CW, which
was further refined with thirty intensive individual inter-
views with adults using the program. Users highly rated
CW’s Comparison Table of the CRCS test options that
summarizes and contrasts ten key aspects of each test:
frequency, preparation, sedation required, discomfort,
embarrassment, inconvenience, accuracy, additional
tests, risk of complications, and cost. CW provides a
unique interactive Preference Clarification Tool, which
helps patients determine the CRCS test option that best
matches their preferences. CW was tested in a pilot ran-
domized controlled trial, which showed that 42% of pre-
viously unscreened patients using CW underwent CRCS
at six months, compared to 20% of those who used a
non-interactive website (P = 0.035). This increase in
CRCS was similar in Caucasians and African Americans;
thus, CW could have higher impact in the latter group
which suffers from a higher CRC burden [48]. To our
knowledge, our pilot randomized controlled trial was
the first published study to show that an interactive,
preference-tailored DA improved CRCS adherence.
However, patients who used CW did not always com-
plete CRCS through their preferred screening test
option. We surmised that the patient-clinician com-
munication during the subsequent clinic visit affected
the final choice, but the pilot trial did not directly ad-
dress this issue.
Our proposed project, Decision Aid to Technologically
Enhance Shared decision making (DATES), will test
CW’s effectiveness for increasing CRCS and its
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rigorous analysis of a conceptual model adapted from
the Theory of Planned Behavior [49-53] (See Figure 1). It
provides a framework that clarifies the relationship be-
tween DAs and SDM [54,55]. The theory incorporates
three patient determinants (attitude, subjective norm
and perceived self-efficacy) that influence patient in-
tention, which in turn influences patient behavior. In
our conceptual model, we have added knowledge to
patient determinants, since DAs increase knowledge
[56,57]. Additionally, based on our pilot randomized
controlled trial, we believe that the patient’s preference
toward a specific CRCS test option is a key mediator be-
tween CW and patient intention to undergo screening
for CRC. Thus, interaction with CW positively affects
patient determinants, leading to the patient establishing
a preference for a particular CRCS test option. This
leads to greater patient intention to undergo screening
and ultimately, higher CRCS rate. This process is also
mediated by what occurs between the patient and the
clinician during the clinic visit to discuss CRCS: the de-
gree of SDM reached and whether the patient and the
clinician agree on which CRCS test option to choose.
The latter will be termed concordance.
We will test an updated version of CW that added an-
other interactive tool, Personal Risk Assessment. The
updated CW also has the reading level decreased from
the previous 11th grade level to eighth grade level. It
uses a renewed platform with faster speed, better graph-
ics, and more straightforward flow, and aligns the CRCS
options to those actually available in the community
practice setting, namely, colonoscopy and stool blood
test. It provides real-time information to the patient and
the clinician during the clinic visit, making CW more
applicable to real-world primary care practices. We will
perform a two-armed randomized controlled trial (300
patients per arm) comparing the intervention arm using
CW to the control arm using a non-interactive website,
Standard Web (SW), in eleven community primary care
and three university family medicine practices in Metro









Figure 1 Conceptual model.Aim 1: to measure the impact of CW on patient uptake of
CRCS
H-1: patients in the intervention arm will have higher
rates of CRCS adherence at the six month follow-up
than those in the control arm.
Aim 2: to evaluate the impact of CW on patient
determinants, patient preference, and patient intention
before the patient-clinician encounter
H2-1: patients in the intervention arm will show greater
improvement from baseline in patient determinants
(knowledge, attitude, subjective norm, perceived self-
efficacy) compared to the control arm after the web
intervention and before the patient-clinician encounter.
H2-2: patients in the intervention arm will be more
likely to have a preference for a particular CRCS test op-
tion than those in the control arm after the web inter-
vention and before the patient-clinician encounter.
H2-3: patients in the intervention arm will have higher
intention to undergo CRCS than those in the control
arm after the web intervention and before the patient-
clinician encounter.
Aim 3: to evaluate the impact of CW on SDM,
concordance, and patient intention during and after the
patient-clinician encounter
H3-1: patients in the intervention arm will experience a
higher level of SDM than those in the control arm
H3-2: higher rates of concordance will be reached be-
tween the patient’s preferred CRCS test and the clini-
cian’s recommended CRCS test in the intervention arm
than those in the control arm.
H3-3: patient’s intention to undergo CRCS after the
patient-clinician encounter will be predicted by the study
arm, degree of SDM, concordance, and interaction bet-
ween SDM and concordance.
Secondary analysis will employ a Structural Equation
Modeling approach to understand the mechanism of the
causal pathway and to test the validity of our proposed
conceptual model [58-61]. Our study will provide de-
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sessment, and that provides real-time information to the
patient and the clinician during the clinic visit, will im-
pact SDM and ultimately, CRCS adherence.Methods/Design
The study is a two-armed randomized controlled trial
with a target of 300 patients per arm. The intervention
arm is CW, the web-based interactive DA that contains
personal risk assessment and preference clarification
tools. The control arm is SW, a non-interactive website
that matches CW in design and content except for the
omission of interactive risk assessment and preference
clarification tools. It should be noted that most US pri-
mary care practices do not routinely use web-based
DAs. SW in the control arm was created to rigorously
assess the effect of the interactive features in CW on the
outcomes detailed in the Aims section. The study proto-
col received ethical approval from the University of
Michigan Institutional Review Board (HUM00044733).Setting
Eleven community primary care (family medicine or in-
ternal medicine) and three university-based family medi-
cine practices in Metro Detroit, Michigan, USA, have
been recruited for the study. The community practices
were recruited through a practice-based research net-
work in the State of Michigan called the Great Lakes
Research Into Practice Network. The university-based
family medicine practices are operated by the depart-
ment of the principal investigator. To ensure clinician
and patient privacy, all practices signed a Data Sharing















University-based Family medicineinstitution. The demographics of the practices are de-
tailed in Table 1.
Practice recruitment, pre-intervention practice
assessment, and clinician survey
Practice recruitment was a multi-step process. First, an
introductory meeting involved the practice clinicians
and staff and the project team (principal investigator,
project manager, research assistant). The visit had two
objectives: to describe the project detail to the practice
personnel, and obtain key information about the practice
and clinicians. Practice and patient information data
were verified through administrative personnel. The cli-
nicians received and signed an informed consent at the
time of the introductory meeting, since data will also be
obtained from them. A clinician survey (see Additional
file 1 for the actual survey; completion time five mi-
nutes), adapted from Murray, was distributed to all
consented clinicians [62,63]. The survey obtained infor-
mation about clinician’s beliefs and practices regarding
CRCS, decision-making style (for example, paternalism,
SDM, informed consumer) [62], and clinician demogra-
phics (for example, specialty, age, gender, race/ethnicity).
During the meeting, each step of the implementation
process was reviewed. Discussions focused on potential
barriers to the implementation and ways to overcome
them. The discussion notes were combined with the
clinician survey for the final practice assessment. At the
present time, the project team is making regular con-
tacts and meetings with the practices to optimize the
implementation process as it pertains to each practice
[63-66]. At the completion of the study, each participa-
ting practice will receive an honorarium of US$1000 for
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The number of participants recruited per practice will
be proportional to the practice size. African Americans
will be overrepresented to comprise 25% of the total pa-
tient number (75 patients per arm). Patients are eligible
for the study if aged between 50 and 75 years; complete
their address and telephone number; are scheduled for a
health maintenance examination or a chronic care visit;
have not undergone a current CRCS procedure (stool
blood test within the past year, flexible sigmoidoscopy
within the past five years, double contrast barium enema
within the past five years, computerized tomography
colonography within the past five years, colonoscopy
within the past ten years); have no dementia or psych-
osis; have no history of CRC; have no medical contra-
indication to CRCS; are able to read and write English;
are able to give informed consent. The research assistant
designated to each practice will review medical records
and prepare a list of eligible patients. The practice clini-
cians will review the list and exclude those that should
not be contacted and why. Each patient will receive an
honorarium of US$25 at the completion of the study
intervention.
Potential risks and protections against them
The potential risks to the patients participating in the
study are violation of their confidential information and
psychological distress. The psychological risks are related
to possible feelings of distress if patients using CW learn
that their risk of CRC is higher than expected. Patients
may also feel distress if their preferred CRCS test option
and the recommended screening test by CW based on
their risk assessment differ. The potential risks to the
clinicians participating in the study are violation of their
confidential information. Every effort will made to
minimize the risk. All data including the digital audio re-
cording will be stored in a secure location with no per-
sonal identifiers in the data. The links to personal
identifiers will be stored in a separate secure location.
The study participant, either the patient or the clinician,
may withdraw from the study at any time point. During
the clinic visit, the patient or the clinician can turn off
the digital audio recorder at any time to block recording
of sensitive discussions. It may be turned back on once
the sensitive discussion is completed. Since all study pa-
tients will be meeting with their clinician, the clinician
will directly address any psychological distress related to
an individual’s participation in the study.
Data and safety monitoring administration
The data and safety monitoring is administered by the
Cancer Prevention Data and Safety Monitoring Com-
mittee within the University of Michigan Comprehen-
sive Cancer Center. The committee reviews projects incancer prevention/biomarker development upon the
request of the principal investigator (PI). The com-
mittee reviews, makes recommendations, and acts on
the following:
 Progress towards completion of the trial - recruitment
and retention of study subjects
 Insufficient accrual to warrant continuation of the
trial
 Evaluation of interim data analyses
 Evaluation of interim new information
 Evaluation of toxicity events including reporting of
adverse events
 Timeliness of data
 Quality of data
 Ethical conduct of research
The Data and Safety Monitoring Committee is em-
powered with the authority to recommend a trial be sus-
pended or terminated based upon concerns in any of the
above areas of review. The committee reviews all serious
adverse events and ensures that these events have been
correctly reported to all institutional review boards, and
that adverse events have been correctly classified as
serious or not serious. The Institutional Review Board
assesses the impact of these events upon the conduct of
the clinical trial. The Institutional Review Board is em-
powered with the authority to suspend or terminate any
trials for which there are concerns of toxicity that
endanger human subjects. Monitoring also considers
factors external to the study, such as scientific or thera-
peutic developments that may have an impact on the
safety of the subjects or the ethics of the study. Recom-
mendations that emanate from monitoring activities are
reviewed by the PI and addressed.
Patient recruitment and consent
Patient recruitment will occur over a period of two-and-
a-half years. (Note: recruitment has started as of May
2012 and is projected to be completed by the end of
September 2014.) The project team will work with prac-
tice staff to identify potentially eligible patients. At a
minimum, the practice electronic billing database, sche-
duling system, and/or medical records will be used to
accomplish this task. Medical records of patients that
are identified as being potentially eligible will be re-
viewed to determine whether they are up to date on
CRCS. If they are not up to date, they will be candidates
for recruitment. The practice clinicians will review their
names and exclude those they identify as meeting the
exclusion criteria described above. Using the clinician-
screened list of potential participants, the project team
will send the Invitation Letter packets. These packets
will be sent in monthly batches, on the first day of each
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their regular visits. The packet will contain an introduc-
tory letter with the practice letterhead and the practice
clinician’s signature and an information brochure that
includes Health Insurance Portability and Accountability
Act privacy notice and information regarding the US$25
honorarium. Patients who do not want further contact
about the study may return an enclosed postage-paid re-
turn postcard or call a toll-free telephone number. One
week after the mailing, the research assistant assigned to
the patient’s practice will call those patients who have
not declined further contact. The research assistant will
make up to five repeat phone calls to those who could
not be reached initially. If patients cannot be contacted
after the repeated phone calls, they will be assumed to
have passively declined, and no further contact will be
made. Once the patients are reached, the research assis-
tant will briefly describe the study and ask about their
interest in participation. Patients who decline will not be
contacted further. For those patients who agree to par-
ticipate, the research assistant will ask them to arrive at
the clinic an hour earlier than the scheduled appoint-
ment. When the patient arrives at the clinic, the research
assistant will present the informed consent form and de-
scribe it and the study in a private room. Those who de-
cline to consent will be thanked and proceed to their
appointment without study participation. Those who
consent will be handed a laptop with wireless Internet
access and proceed with the study as detailed below.
Patient baseline survey
The participating patients will enter the website and will
first complete the patient baseline survey (see Additional
file 2 for the actual survey; completion time: 15 minutes).
The survey will assess patient demographics; past experi-
ence with CRC screening; knowledge, attitude, subjective
norm, and perceived self efficacy about CRC screening;
preferred CRC screening test option; and intent to
undergo screening for CRC.
Randomization of the patients to the intervention arm
and the control arm
After completing the patient baseline survey, the com-
puter program will randomize the patients into the
intervention arm and the control arm. The randomi-
zation will be stratified by practice, gender, and race to
ensure there are equal proportions of patients by these
factors in both arms.
Delivery of the DA intervention (CW/SW)
After randomization, the participating patients will enter
the introductory page for CW for those randomized to
the intervention arm and SW for those randomized into
the Control Arm. In the intervention arm, the patientswill access and work through CW. On entering CW, the
patient will be guided to Overview, then Personal Risk
Assessment, where they will interactively answer ques-
tions about their personal and family health history.
There will be immediate feedback on whether they are
‘Average Risk’, ‘Increased Risk’, or ‘Unknown Risk’ (this
occurs if the patient, who is otherwise average risk, an-
swers ‘I don’t know’ to any of the questions in the Per-
sonal Risk Assessment). Next, the patients will be guided
to access the Comparison Table providing information
on CRCS tests (see Figure 2) and a Preference Clarifica-
tion Tool from which they may select the three most im-
portant issues of a CRCS test (see Figure 3). The test
most closely matching the three selected issues will be
provided. The patients may work on the tool for as long
as they wish. Once they select the matched test, a Feed-
back Page reviewing their test of choice in the context of
their risk will be provided: ‘Average Risk’, ‘Increased Risk’,
or ‘Unknown Risk’. The combination of patient risk pro-
file and preference will help the patients to understand
the details of CRCS, how each test correlates with their
preference, their risk for CRC, and how their preference
may or may not match the recommended test based on
their risk. They will be given a final opportunity to select
a CRCS test based on their risk and preferences. Once
they submit their choice, a Summary Page will appear
that shows them: their risk, their three most important
issues, CRCS test based on the three issues, and the test
they ultimately selected. Participating patients in both
intervention and control arms will undergo the interven-
tion in a private room. For patients needing help using
the computer, the research assistant will provide this
support but will not counsel them on CRCS. These pro-
visions will ensure privacy, standardization, and inclu-
sion of patients without Internet access and low
computer literacy and skills.
CW and SW data retrieval protocol
For both CW and SW, the following data will be re-
trieved: time from login to logoff; frequency/duration
each screen page was accessed; CRCS test option
selected.
Patient post-web survey
The survey (see Additional file 3 for the actual survey;
completion time: ten minutes) will be administered on-
line immediately after the DA intervention (CW or SW).
The survey will assess patient’s knowledge, attitude, sub-
jective norm, and perceived self efficacy about CRC
screening; preferred CRC screening test option; and in-
tent to get screened for CRC. It will also include
manipulation-check questions to assess what compo-
nents of CW were most helpful for the patients in
selecting a CRCS test option.
Figure 2 Screen shots of ColoDATES Web (Figures 2A-2E).
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The research assistant will have a portable printer to en-
sure that the Summary Page is provided to the patientand clinician prior to the appointment. Clinicians will
not be aware of which arm (intervention arm or control
arm) the patient will be in since patients from both arms
Figure 3 Structural equation model.
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way that it is not clear which Summary Page constitutes
the intervention arm and the control arm.
It should be noted that the clinicians are free to make
their own recommendation, and should they disagree
with the patient’s choice of CRCS test option, may re-
commend another option. This may occur when a pa-
tient prefers a CRCS test other than colonoscopy, since
clinicians increasingly prefer colonoscopy for CRCS, as
shown in previous studies [35,36], our preliminary sur-
vey to the primary care practices, and a recent state-
wide survey of Michigan physicians [67]. However,
current guidelines do not recommend colonoscopy over
other CRCS options [1,3], and ultimately, due to lack
of colonoscopy access, insurance, and other reasonsincluding patient preference, a CRCS test other than col-
onoscopy may be selected.
Digital audio recording of patient-clinician encounter/
OPTION scale
Both intervention and control arms will undergo audio
recording. The research assistant will place a small
digital audio recorder in the examination room just be-
fore the patient/clinician encounter, turn it on, and leave
the room. During the encounter, the patient or clinician
can turn off the digital audio recorder at any time to
block recording of sensitive discussions. It may be
turned back on once the sensitive discussion is com-
pleted. At the end of the encounter, the research assis-
tant will retrieve the recorder, turn it off, remove the
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a secure server with the corresponding code. The inves-
tigators (PI, project manager, and three co-investigators)
will read all transcripts to assign an Observing Patient
Involvement (OPTION) score. The OPTION scale (see
Additional file 4 for the actual form) is a validated
12-item instrument considered to be the most efficient
and sensitive SDM coding system for research purposes
[68-71]. Because the OPTION scale focuses on a single
agenda during a patient-clinician encounter, and assesses
to what degree clinicians involve patients in SDM, it is
well suited to assess how the patient activated by CW af-
fects the clinician’s SDM performance. The trained ob-
servers will listen to the audio recorded portion of the
visit pertaining to CRCS and assign raw scores for each
of 12 constructs in SDM, which will be converted to a
scale of 0 to 100, with 0 indicating minimum and 100 in-
dicating maximum degree of SDM. The observers will
be blinded to the study arm (intervention arm or control
arm) assignment, patient name, clinician name, and clin-
ical site. The audio recording occurs in both study arms;
therefore, no observational bias would be introduced
into the comparison of the study arm interventions.
Patient post-encounter survey
The research assistant will administer this survey (see
Additional file 5 for the actual survey; completion time:
five minutes) by paper to the patient after the patient-
clinician encounter. The survey will assess patient’s pre-
ferred CRCS test; whether concordance was achieved
with the clinician (that is, whether the clinician's final
CRCS test recommendation matched the patient’s pre-
ferred CRCS test option); whether the patient felt his/
her role in deciding to get checked for CRC was just
right, tilted too much towards the clinician or too much
toward the patient; and intent to undergo screening
for CRC.
Administering the endpoint chart audit and survey
Six months from the patient visit, the chart will be
audited by the research assistant (see Additional file 6
for the actual audit form). Information on CRCS avail-
able in the medical chart will include stool blood test,
flexible sigmoidoscopy, double contrast barium enema,
computerized tomography colonography, and colonos-
copy. Further, we will ascertain follow-up procedures
used with patients who have an abnormal CRCS test re-
sult. Patients without medical record documentation will
be called to check whether or not CRCS had been done
and, if so, type of test and by which clinician/practice. If
the clinician/practice identified is outside of the partici-
pating clinician/practice of the study, we will obtain a re-
lease of information for medical records from these
outside sites to confirm the self-report. If a release is notprovided or medical records cannot confirm the self-
report, the patient will be coded as not having com-
pleted CRCS. The only acceptable outcome endpoint
will be a medically documented CRCS procedure. Self-
report of completing CRCS with no documentation, and
self-report of not completing CRCS, will be coded as no
CRCS done [72-79]. Documented incomplete CRCS test
(for example, unsuccessful colonoscopy, incomplete num-
ber of stool blood cards submitted) will be coded as in-
complete CRCS. Thus, there will be no missing data for
this outcome endpoint. In addition to ‘CRCS done’, ‘CRCS
incomplete’, and ‘CRCS not done’, information on the type
of CRCS test done will be collected.
Data collection instruments
Table 2 summarizes the data collection instruments with
respect to source and time point of collection. Post-web
survey will include manipulation-check questions. Also,
data regarding patient’s CW/SW usage will be retrieved.
They will allow us to check whether the patients in the
intervention arm actually used the interactive tools in
CW and found them to be useful. A more detailed table
that correlates each question of the surveys with the do-
mains of the conceptual model is included in Additional
file 7.
Analysis
In the year following the end of six-month chart audit
(April 2015 to March 2016), we will complete data ana-
lyses to test study hypotheses.
Aim 1: to measure the impact of CW on patient uptake of
CRCS
H-1: patients in the intervention arm will have higher
rates of CRCS adherence at the six month follow-up
than those in the control arm.
The study arms will be compared to assure that
randomization achieved similar study population with
respect to age, gender, race, previous CRCS, practice site,
and data completion. Medically documented completion
of CRCS will be compared between the intervention arm
and the control arm by means of a chi-square test (un-
adjusted analysis) and a logistic regression adjusting for
potential predictors at baseline. The regression analysis
will be performed with data at the patient level with
completing CRCS (yes/no) as the outcome measure and
the arm assignment (intervention arm versus control
arm) as the main covariate of interest. The practice indi-
cator will further be included as a covariate in order to
account for the variation between practices. The cluster-
ing effect due to clinician will be accounted for by using
a generalized estimating equations approach. Personal
patient-level background information (for example, age,
race, education, marital status, smoking, health status,







chart auditBaseline Post-web Post-encounter




Subjective norm × × ×
Perceived self efficacy × ×
Patient preference × × ×
Manipulation-check questions ×
Clinician decision making Style ×
Shared decision making × ×
Concordance × ×
Patient intention × × ×
Action (CRCS) ×
Method of collection web web paper paper recording medical chart
x: Signifies that the mediators and outcomes in question were addressed in the survey, recording or audit.
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http://www.trialsjournal.com/content/14/1/381health insurance) from the patient baseline survey will
be considered for inclusion in the regression model. The
model will further be adjusted for information about the
patient’s past experience with the CRCS procedures and
the baseline level of patient determinants (for example,
knowledge, attitude, subjective norm, self-efficacy) and
intent. We will also adjust for OPTION score and per-
tinent clinician-level covariates such as the clinician’s
communication style from the clinician survey. In order
to understand whether there is any difference in the
completion of CRCS rates between groups of patients
who (a) complete the risk assessment tool only, (b)
complete the preference clarification tool only, (c) com-
plete both, and (d) complete neither, we will use a four
level factor indicating this group membership as an in-
dependent variable in the regression model.
The contribution of a specific group of covariates
will be measured by means of increase in generalized
R-square defined as:






2 are the likelihood ratio statistics of the
smaller and larger models, respectively.
Variable selection
In view of a potentially large number of candidates for
inclusion as covariates, we will use a simple screening
method as follows. Each potential covariate will be in-
vestigated for confounding effect by running a prelimin-
ary screening analysis with and without the covariate in
the model along with the study arm and retaining theones for the final logistic regression model, which either:
(a) have a significant effect on the outcome; or (b)
change the co-efficient of the study arm variable by
more than 5%. Moderating effect of a potential covari-
ate × will be investigated by including a study arm ×
interaction term in the model.Handling missing data
Missing covariate values for the subject-level informa-
tion will be imputed using multiple imputation methods.
All missing values will be imputed using the chained
equation method that allows both categorical and con-
tinuous variables to be imputed together without making
any multivariate joint distributional assumption [80].
Finally, we will combine the results from ten imputed
datasets using Rubin’s formula [81].Aim 2: to evaluate the impact of CW on patient
determinants, patient preference, and patient intention
before the patient-clinician encounter
H2-1: patients in the intervention arm will show greater
improvement from baseline in patient determinants
(knowledge, attitude, subjective norm, perceived self-
efficacy) compared to the control arm after the web
intervention and before the patient-clinician encounter.
H2-2: patients in the intervention arm will be more
likely to have a preference for a particular CRCS test op-
tion than those in the control arm after the web inter-
vention and before the patient-clinician encounter.
H2-3: patients in the intervention arm will have higher
intention to undergo CRCS than those in the control
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clinician encounter.
We will test Hypothesis H2-1 by means of linear
regression analysis. We will use a separate model for
each determinant. In each case, the post-web aggre-
gated score for the scale under consideration will be
used as the dependent variable. As before, the arm
assignment (intervention arm versus control arm) will
be the primary independent factor. The model will be
further adjusted for the baseline score of the corre-
sponding determinant and the patient-level demo-
graphic information.
Hypothesis H2-2 will be investigated by a logistic re-
gression analysis with a dichotomous outcome indicating
whether or not the subject has a clear preference for a
CRCS test option in the patient post-web survey. This
analysis will be undertaken only for the subgroup of sub-
jects in either arm who did not have a clear preference
at baseline. The demographic information will be used
as independent variables as before.
Hypothesis H2-3 will be investigated using a model
similar to that for Hypothesis H2-1, but the patient
intention post-web will replace the patient determinants
post-web as outcome, and the patient intention score at
baseline will replace the patient determinants at baseline
as independent variable.
Aim 3: to evaluate the impact of CW on SDM,
concordance, and patient intention during and after the
patient-clinician encounter
H3-1: patients in the intervention arm will experience a
higher level of SDM than those in the control arm.
H3-2: higher rates of concordance will be reached bet-
ween the patient’s preferred CRCS test and the clini-
cian’s recommended CRCS test in the intervention arm
than those in the control arm.
H3-3: patient’s intention to undergo CRCS after the
patient-clinician encounter will be predicted by the study
arm, degree of SDM, concordance, and interaction bet-
ween SDM and concordance.
We will test Hypothesis H3-1 by means of multiple
linear regression with the OPTION score as the out-
come. Otherwise the analytical strategy will be identical
to that in aim 1. Hypothesis H3-2 will be investigated by
a logistic regression analysis with a dichotomous out-
come indicating whether or not the subject’s preferred
CRCS test option matched with the clinician’s recom-
mendation. Once again the analytical strategy will be
similar to that in aim 1. To investigate the independent
effect of SDM on concordance, we will include the OP-
TION score as a covariate in the regression model.
Hypothesis H3-3 will be studied by a multiple linear
regression analysis with the patient intention after the
patient-clinician encounter (post-encounter) as theoutcome. The primary predictors in the model will be
the study arm, the OPTION score, concordance, and
the interaction between the OPTION score and con-
cordance. The interaction term allows us to investigate
any differential association within SDM and intention be-
tween the concordant and the discordant groups. The
model will further be controlled for the patient intention
before the patient-clinician encounter. The analytical
strategy will be similar to that in aim 1.
Secondary analysis will be carried out by means of
Structural Equation Modeling approach to estimate the
parameters of the analysis model (Figure 4) that corre-
sponds to the conceptual model (Figure 1) [49,58-61].
Specifically, a path analysis will estimate the direct and
indirect effects in order to identify the significance or
otherwise of specific causal relationships. These will be
done by standard t or F-tests in the context of a multiple
regression analysis. Testing mediation (indirect) effects
will further require using Sobel’s formula [82]. Mode-
ration is investigated by testing for significance of hy-
pothesized interaction terms or interaction effects that
are identified during the initial screening. The analysis
model will have several variables: subjective norm,
perceived self efficacy, patient preference, and patient
intention, each measured longitudinally; concordance,
measured at one time point; practice indicators, interven-
tion arm versus control arm, clinician communication
style, SDM, and patient behavior/action each measured
once along with the covariates identified during the pre-
liminary screening. Figure 4 illustrates the full complexity
of the theorized causal pathway.
Structural Equation Modeling will allow us to (a) iden-
tify the significant direct and indirect effects in specific
causal relationships and (b) test the plausibility of the
overall model or parts thereof. In the unlikely event that
the aims are not met, the information obtained will still
lead us to better understand how DAs affect patient be-
havior and SDM between the patient and the clinician.
Sample size and power
In aims 1, 2 and 3, we make comparisons between the
intervention arm and the control arm. The effect size we
wish to detect between the study arms is 15%. Based on
published data [48], the estimated proportion of study
participants in the control arm that will complete CRCS
by six months post intervention is 10 to 15%. Based on
the pilot randomized controlled trial, the proportion is
slightly higher (approximately 24%). We take this higher
value as the anticipated rate in the control arm after six
months, since this gives more conservative (larger) sam-
ple size estimates. To detect with 90% power a 15% in-
crease in the completion rate in the intervention arm to
be significant, one needs to have 213 patients per study
































Figure 4 Sample selection and attrition.
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with 5% type-I error rate. Since we target to recruit 300
patients in each study arm, with a rough balance across
practice, race, and gender, we have good power to detect
such differences in the gender subgroups as well. For ex-
ample, assuming that we have 150 men in each study
arm, we have 76% power to detect the effect size des-
cribed herein. With 300 patients per arm, a standardized
mean difference of 0.23 can be detected between the two
arms for continuous outcomes with 80% power. For di-
chotomous outcomes such as concordance, a 15% dif-
ference between the two arms can be detected with a
power of ≥ 80%, when the percentage of occurrence in
the control arm ranges between 25% and 50%. Thus, we
are adequately powered to detect small differences for
all aims. For the Structural Equation Modeling analysis,
we estimate that the conceptual model will have > 100
degrees of freedom. Assuming a sample of 600 patients,
power will be > 99% for a test of the overall model.
Power to reject the model will be assessed by root mean
square error of approximation [83].
Discussion
Rationale for undergoing the trial
The results of our proposed randomized controlled trial
will be among the first to examine the effect of a real-time preference assessment exercise on CRCS and medi-
ators, and, in doing so, will shed light on the patient-
clinician communication and SDM ‘black box’ that
currently exists between the delivery of DAs to patients
and the subsequent patient behavior (that is, CRCS ad-
herence). Our conceptual model will elucidate not only
the mechanism of how a DA influences patient behavior,
but also how the DA affects the SDM between the
patient and the clinician [58-61]. In addition, CW has
several highly innovative features. First, CW is an inter-
active web-based DA rigorously developed through ex-
tensive formative research [46-48]. Second, CW assists
patients in clarifying their own CRCS preferences and
risk. To our knowledge, no previous tools have inte-
grated interactive preference clarification and personal
risk assessment to tailor CRCS recommendation, not
just assessing them separately [36]. Third, CW offloads
the time devoted to providing knowledge, preference
clarification, and risk assessment from the clinic visit,
permitting the patient and clinician to engage in SDM at
a more advanced level. Fourth, it can be easily incorpo-
rated into routine clinical care.
Randomization strategy
Randomizing at the patient level facilitates recruitment
and makes the study more feasible to complete in the
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in balancing across potential patient level confounders
and increases statistical power to detect an intervention
effect. Clinicians will be blinded to the randomization.
We considered randomization at the level of the prac-
tice. Such a design would be necessary if there was a risk
of contamination between the intervention arm and the
control arm within a practice if randomization occurred
at the patient level. This is not a concern in our pro-
posed project for two reasons. First, patients in the inter-
vention arm will not have access to SW, and patients in
the control arm will not have access to CW. Second,
clinicians will not have the resources (time, expertise,
desire) to replicate the CW experience. The clinicians
could give an information brochure that replicates the
SW content, but this would only be additive at best
to either CW in the intervention arm or SW in the
control arm.
Alternative strategies
We considered providing the DA intervention through a
compact disc. However, this would add substantial cost
to the development. Also, an Internet-based approach
would be much more feasible for future dissemination.
We also considered recruiting patients without health
insurance but decided to focus our efforts on over-
sampling African Americans, to test in the community
practices our pilot randomized controlled trial finding
that CW led to increased CRCS adherence in both Cau-
casians and African Americans. We decided to provide
CW in English only for this study, so that we could
prove its effectiveness first before expanding to other
languages, such as Spanish, with their attendant costs.
Finally, because our focus was on how CW affects SDM
between the patient and the clinician in community
practices, we needed patients who had a primary care
clinician and did not recruit patients without a primary
care clinician.
Since CW has interactive risk assessment and prefe-
rence clarification, we considered a 2 × 2 design of inter-
active risk assessment (+/−) and preference clarification
(+/−). We also considered a three-arm study of SW, CW
with interactive preference clarification only, and CW
with interactive risk assessment and preference clarifica-
tion. We ultimately decided against these designs due to
feasibility and cost concerns in a multi-site community
practice setting and the input from the practice clini-
cians that CW without risk assessment had no clinical
utility. We utilize manipulation-check questions to
understand what particular features of CW in the
intervention arm were instrumental in the differential
outcomes.
Ideally, the CW would be available to patients to
complete from home prior to an appointment, therebynot requiring them to come an hour before an appoint-
ment. The original proposed study design was to have
patients complete the website exposure from home with
telephone assistance if needed. Reviewers expressed con-
cern that this design would lead to significantly different
experiences for each patient. Some might do it weeks
ahead of time leading to discussion with many others
about the decision. Others would wait to the very last
minute to do it. Also, without the research team verifica-
tion, a person other than the intended participant may
actually log in to the website. The reviewers felt it was
critical that everyone have the same exposure. The re-
search team made the change with concerns that this
would impair recruitment of clinicians and patients.
However, this has not been a barrier to date.
Dissemination
The participating clinicians receive regular newsletters
and Email updates about the study. Upon completion of
the study and analysis of data for the primary hypoth-
esis, the participating clinicians will receive a summary
report and be invited to meet with the PI for discussion.
The participating patients will receive a summary letter
about the results. Updates about the findings will be
posted in each participating clinical site.
The data including audiotapes will be open to other
investigative teams for additional analysis by contacting
the PI with a formal request. Contact information will
be provided with all presentations and publications. The
request form is available as Additional file 8. Each re-
quest will be reviewed by the research team and the
Data and Safety Monitoring Committee for approval.
Future directions
Once our aims are accomplished, we can use the barrier
and facilitator information to move into dissemination
of the intervention, and address the issues above. Differ-
ent language versions of CW can be created and tested.
For dissemination, CW needs to be modified to a de-
liverable product that can be used alone, integrated into
other’s website or electronic medical record, or used
with mobile devices. Also, since we will now have in-
formation on how CW affects patient-clinician com-
munication, CW can be tested as a community-wide
intervention with particular efforts to target the patients
without health insurance and/or PC clinicians. The re-
corded patient-clinician encounter will be a rich source
of data for further exploration focused on communica-
tion, SDM, and competing demands addressed in the
clinic visit. We are particularly interested in further
examining the characteristics of patients and clinicians
whose preferred decision making style leans towards
SDM. In addition, we will have data related to facilitators,
barriers, and cost to implement CW in community-based
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cost effective simulation of CW.
Trial status
Patient recruitment started in May 2012 and will con-
tinue through the end of September 2014. As of 28
October 2013, the study has recruited 339 participants
(target: 600).
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